Related Experiment Video
Updated: Mar 24, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
A triterpenoid from wild bitter gourd inhibits breast cancer cells
Li-Yuan Bai1,2,3, Chang-Fang Chiu2,3, Po-Chen Chu4,5
1Division of Hematology and Oncology, Department of Internal Medicine , China Medical University Hospital, Taichung 404, Taiwan.
Abstract:
The antitumor activity of 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al (TCD), a triterpenoid isolated from wild bitter gourd, in breast cancer cells was investigated. TCD suppressed the proliferation of MCF-7 and MDA-MB-231 breast cancer cells with IC50 values at 72 h of 19 and 23 μM, respectively, via a PPARγ-independent manner. TCD induced cell apoptosis accompanied with pleiotrophic biological modulations including down-regulation of Akt-NF-κB signaling, up-regulation of p38 mitogen-activated protein kinase and p53, increased reactive oxygen species generation, inhibition of histone deacetylases protein expression, and cytoprotective autophagy. Together, these findings provided the translational value of TCD and wild bitter gourd as an antitumor agent for patients with breast cancer.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Prevention
Some...
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

